TYPHOID CONJUGATE VACCINE

Image

Introduction

Typhoid is spread by infected human waste, so safe food, clean water, improved sanitation, and good hygiene (WASH) practices are key to preventing the disease. Because of the significant burden of typhoid and the growing threat of drug resistance, the role of vaccines alongside WASH interventions is critical in high-risk, typhoid-endemic areas. This is especially important among rural and hard-to-reach communities where progress in medical services, infrastructure, and development may be slow. Additionally, typhoid vaccines are valuable for travelers, food workers (including street vendors), household contacts of typhoid carriers, and laboratory workers.

CompositionTyphoid (polysaccharide) conjugate vaccine

Suspension for injection in multidose vial, for IM injection into the anterolateral part of the thigh in children < 2 years and into the deltoid muscle in children.

Dosage and vaccination schedule

Child and adult: 0.5 ml single dose

Routine vaccination

Child at 9 months or during the 2nd year of life: one single dose at the same time as other recommended vaccines. Follow national recommendations.

Catch-up vaccination: Child up to 15 years: one single dose.

Vaccination schedule

  • Single dose at 9-12 through 23 months followed by a booster at 2 years of age
  • Single dose at 9-12 through 23 months followed by a booster at 2 years of age
  • Single dose at 2 years
  • Revaccination every 3 years

Side effects

  • Injection site reactions (pain, tenderness, redness, swelling, or a hard lump),
  • Low fever,
  • Nausea,
  • Diarrhea,
  • Stomach pain, or
  • Headache.

Conclusion 

 Our Journal is planning to release a year end special issue to celebrate its journey for publishing articles with in the short time.

 A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing.

Manuscripts can be forwarded to the Editorial Office at autoimmunedis@eclinicalsci.com

How we work:

  • After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
  • A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
  • Author proof is generated within 7 working days after the acceptance decision.

 

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Color Art: In a world of black & white journal articles, high-quality full-color images make your article stand out from the crowd and tell a complete story, increasing readers and citations.

Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.

Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.

 

Media Contact:
John Kimberly
Editorial Manager
Journal of Vaccines & Vaccination
Email: jvv@scholarlypub.com